
Who We Are
BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.
Guided by our purpose to develop medicines that make a profound impact on people’s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.
Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.
About Corporate Groups
It takes a village, and at BioMarin, our general and admin teams are the village behind our success. From the IT experts who manage our technology to the human resources professionals who hire the people who make it all possible, these teams support our organization and span all areas of operations.
Global Process Owner, Source to Pay BioMarin has experienced substantial growth organically since its inception, primarily over the last decade. This steady growth in both cost structure and staff were essential to BioMarin’s emergence as a leading, fully integrated global biopharmaceutical company with approximately $2 billion in revenues from over 75 countries, a robust R&D pipeline, operating profits, and world-class technical capabilities through its 3,000 employees worldwide. As the company grows, BioMarin leadership desires to optimize the efficiency of its operations for the future through its next phase of growth. In 2022 BioMarin launched its Enterprise Resource Planning (ERP) enterprise-wide operational initiative transforming the way we work by implementing an ERP system solution, SAP S4 HANA.In Q1, 2025 our first five legal entities went live in SAP, the remaining entities will go live in Q1, 2026.Implementing a new ERP impacts the entire company – putting this system in place is equally complex and transformational. The project team is built around the Global Process Workflows as outlined below:
The Global Process Owner (GPO) for each workflow is accountable for the development and integration of the workstream into the overall program and the workstream specific Process Leads will report to them. We are actively recruiting a Global Process Owner for Source to Pay.Key responsibilities:
Critical Attributes The Global Process Owner will be a role that requires a growth mindset and dynamic set of business and collaboration skills, including the following:
Note: This description is not intended to be all-inclusive, or a limitation of the duties of the position. It is intended to describe the general nature of the job that may include other duties as assumed or assigned.
Equal Opportunity Employer/Veterans/Disabled
An Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.

Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders. The more innovative solutions developed, the more lives BioMarin can impact.
Recruitment Fraud Alert Notice
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent BioMarin in recruitment activities. We have an established recruitment process which is required for all posted positions by BioMarin prior to issuing an offer of employment. This BioMarin process requires formal interviews conducted live with personnel representing BioMarin and never requires payments or fees from job applicants. BioMarin does not conduct interviews via texting tools such as RingCentral.
In the event you receive a suspicious email message about recruiting on behalf of BioMarin, unless it’s from a BioMarin authorized recruiting partner, do not provide any personal information or pay any fees. Qualified and interested candidates should apply to current openings directly through this BioMarin website. BioMarin accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.
If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the FBI via www.ic3.gov. We would also suggest you notify your local police department and monitor your credit.
We appreciate your interest in BioMarin & encourage you to visit http://careers.biomarin.com/career-areas to review job opportunities.